MedPath

Accord BioPharma's Ustekinumab Biosimilar BLA Accepted by FDA, Launch Expected by May 2025

• Accord BioPharma's Biologics License Application (BLA) for DMB-3115, a biosimilar to Janssen's Stelara® (ustekinumab), has been accepted by the US FDA. • DMB-3115 was jointly developed by Dong-A ST and Meiji Seika Pharma, with Intas Pharmaceuticals holding exclusive licensing rights, excluding specific Asian countries. • Accord BioPharma reached a settlement with Janssen in October 2023, allowing for a US launch of DMB-3115 no later than May 15, 2025, pending FDA approval.

Accord BioPharma, a subsidiary of Intas Pharmaceuticals, has announced that the FDA has accepted its BLA for DMB-3115, a proposed biosimilar to Janssen’s Stelara® (ustekinumab). This acceptance marks a significant step toward providing a more affordable treatment option for patients requiring ustekinumab. The settlement with Janssen permits launch by 15 May 2025.
DMB-3115 was jointly developed by Dong-A ST and Meiji Seika Pharma. Intas Pharmaceuticals holds exclusive worldwide licensing rights, excluding certain Asian countries, per an agreement announced in 2021. Accord BioPharma will handle the commercialization of DMB-3115 in the United States.
The settlement agreement reached with Janssen in October 2023 paves the way for Accord to launch DMB-3115 in the US market by May 15, 2025, contingent upon FDA approval. This development promises to introduce competition in the ustekinumab market, potentially lowering costs and increasing patient access to this important biologic medication.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Steqeyma and Yesintek: Expanding Biosimilar Options for Stelara

The FDA has approved Steqeyma (ustekinumab-stba) and Yesintek (ustekinumab-kfce) as biosimilars to Stelara, offering new options for patients with autoimmune and inflammatory conditions.
Steqeyma and Yesintek are approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, mirroring Stelara's indications.

FDA Accepts Biologics License Application for Denosumab Biosimilar HLX14

The FDA has accepted Organon and Shanghai Henlius Biotech’s BLA for HLX14, a denosumab biosimilar, potentially expanding treatment options for osteoporosis and bone-related conditions.
HLX14's BLA submission includes data from comparative analytical studies and clinical trials, demonstrating its similarity to the reference drug, Prolia.

FDA Approves New Intravenous Formulation of Ustekinumab Biosimilar SELARSDI™

The FDA has approved a new intravenous formulation of SELARSDI™ (ustekinumab-aekn), a biosimilar to STELARA® (ustekinumab), expanding its potential use.
This new presentation of SELARSDI™, a 130 mg/26 mL single-dose vial for intravenous infusion, complements the existing subcutaneous injection formulations.

FDA Approves New IV Formulation of Selarsdi (ustekinumab-aekn) for Expanded Indications

The FDA has approved a new intravenous formulation of Selarsdi (ustekinumab-aekn), a biosimilar to Stelara, expanding its potential uses.
This approval aligns Selarsdi's label more closely with Stelara's indications in the U.S., including use for gastrointestinal diseases.

FDA Approves Accord BioPharma's IMULDOSA, a Biosimilar to Stelara, for Inflammatory Conditions

The FDA has approved IMULDOSA (ustekinumab-srlf), a biosimilar developed by Accord BioPharma, for treating chronic inflammatory conditions..
IMULDOSA is indicated for conditions including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, expanding treatment options.

FDA Approves New IV Infusion Presentation of Selarsdi (ustekinumab-aekn) Biosimilar

The FDA has approved a new intravenous infusion formulation of Selarsdi (ustekinumab-aekn), a biosimilar to Stelara, expanding its potential use.
This approval aligns Selarsdi's label more closely with Stelara's indications, including Crohn's disease and ulcerative colitis, ahead of its U.S. launch.

Imuldosa (Ustekinumab-srlf) Receives FDA Approval as Stelara Biosimilar

Imuldosa, a biosimilar to Stelara, has been approved by the FDA for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Developed by Dong-A ST and Meiji Seika Pharma, Imuldosa demonstrated similar pharmacokinetic characteristics, safety, tolerability, and efficacy to Stelara in clinical trials.

Bio-Thera Solutions' Ustekinumab Biosimilar BAT2206 Gains Regulatory Acceptance in US and EU

Bio-Thera Solutions announced FDA acceptance of the BLA for BAT2206, a proposed interchangeable biosimilar to Stelara® (ustekinumab), seeking US commercial license.
The EMA has also accepted Bio-Thera's MAA for BAT2206, a biosimilar to Stelara®, marking the first ustekinumab biosimilar from a Chinese company submitted to both agencies.

FDA Approves Alvotech/Teva's Ustekinumab Biosimilar for Psoriasis and Psoriatic Arthritis

The FDA has approved SELARSDI (ustekinumab-aekn), a biosimilar developed by Alvotech and commercialized by Teva, for treating moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients aged 6 and older.

FDA Grants Priority Review to Lecanemab for Early Alzheimer's Treatment

The FDA has accepted Eisai's Biologics License Application (BLA) for lecanemab, an anti-amyloid beta protofibril antibody, for treating mild cognitive impairment due to Alzheimer's disease.
Lecanemab has been granted Priority Review, setting a PDUFA action date for January 6, 2023, potentially expediting access for patients with early Alzheimer's.

Reference News

[1]
Accord’s BLA for its Ustekinumab (Stelara®) Biosimilar Accepted by FDA; Settlement with Janssen Permits Launch by 15 May 2025 | Pearce IP
pearceip.law · Jan 4, 2024

Accord BioPharma's BLA for DMB-3115, a biosimilar to Janssen’s Stelara®, accepted by FDA. Developed by Dong-A St and Mei...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy